Uveal melanoma: In the era of new treatments

Lactate metabolism and lactylation in uveal melanoma: from metabolic adaptation to immune regulation
Yingluan Wang, Zhan Cao, Dawei Sun +1
Frontiers in immunology16 Oct 2026Peer-reviewedCC BYFull textImmunologyEurope PMC
114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)
Justin Moser, Jose Lutzky, Andrew Elliott +7
Journal for ImmunoTherapy of Cancer6 Nov 2026Peer-reviewedCC BYFull textImmunology OncologyDOAJ
Tebentafusp induces systemic immune activation, but tumor immune remodeling remains incompletely validated: a narrative review in metastatic uveal melanoma
Francesca Rifaldi, Filippo De Braud, Michele Del Vecchio +1
Frontiers in Immunology12 Oct 2026Peer-reviewedCC BY 4.0Full textImmunologyPMCCrossrefEurope PMC
A machine learning-assisted hypoxia-associated prognostic model reveals PFKP-mediated glycolytic regulation in uveal melanoma
Kunxia Lin, Yi Cui, Yuzhe Jiang +5
Frontiers in Immunology5 Nov 2026Peer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
Editorial: Advancing enteric disease treatments: probiotics and antimicrobial strategies
Vijay Morampudi
Frontiers in Immunology28 Oct 2026Peer-reviewedCC BY 4.0Full textImmunologyCrossref

Cite

BibTeX

@article{mylene2026uveal,
  title = {{Uveal melanoma: In the era of new treatments}},
  author = {Wespiser Mylène and E. Neidhardt and S. Negrier},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  month = sep,
  doi = {10.1016/j.ctrv.2023.102599},
  url = {https://hal.science/hal-05750209v1},
}

RIS

TY  - JOUR
TI  - Uveal melanoma: In the era of new treatments
AU  - Wespiser Mylène
AU  - E. Neidhardt
AU  - S. Negrier
PY  - 2026
DA  - 2026/09/15
JO  - Cancer Treatment Reviews
DO  - 10.1016/j.ctrv.2023.102599
UR  - https://hal.science/hal-05750209v1
SN  - 0305-7372
ER  -

Related

Cite